Skin Toxicity After Exposure to Gadolinium-Based Contrast Agents in Normal Renal Function, Using Clinical Approved Doses

Objectives The aim of this study was to summarize the current preclinical and clinical evidence on the association between exposure to gadolinium (Gd) compounds and skin toxicity in a setting similar to clinical practice. Materials and Methods A search of MEDLINE and PubMed references from January 2000 to December 2022 was performed using keywords related to gadolinium deposition and its effects on the skin, such as “gadolinium,” “gadolinium-based contrast agents,” “skin,” “deposition,” and “toxicity.” In addition, cross-referencing was added when appropriate. For preclinical in vitro studies, we included all the studies that analyzed the response of human dermal fibroblasts to exposure to various gadolinium compounds. For preclinical animal studies and clinical studies, we included only those that analyzed animals or patients with preserved renal function (estimated glomerular filtration rate >30 mL/min/1.73 m2), using a dosage of gadolinium-based contrast agents (GBCAs) similar to that commonly applied (0.1 mmol/kg). Results Forty studies were selected. Preclinical findings suggest that Gd compounds can produce profibrotic responses in the skin in vitro, through the activation and proliferation of dermal fibroblasts and promoting their myofibroblast differentiation. Gadolinium influences the process of collagen production and the collagen content of skin, by increasing the levels of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1. Preclinical animal studies show that Gd can deposit in the skin with higher concentrations when linear GBCAs are applied. However, these deposits decrease over time and are not associated with obvious macroscopic or histological modifications. The clinical relevance of GBCAs in inducing small fiber neuropathy remains to be determined. Clinical studies show that Gd is detectable in the skin and hair of subjects with normal renal function in higher concentrations after intravenous administration of linear compared with macrocyclic GBCA. However, these deposits decrease over time and are not associated with cutaneous or histological modifications. Also, subclinical dermal involvement related to linear GBCA exposure may be detectable on brain MRI. There is no conclusive evidence to support a causal relationship between GBCA administration at the clinical dose and cutaneous manifestations in patients with normal renal function. Conclusions Gadolinium can produce profibrotic responses in the skin, especially acting on fibroblasts, as shown by preclinical in vitro studies. Gadolinium deposits are detectable in the skin even in subjects with normal renal function with higher concentrations when linear GBCAs are used, as confirmed by both preclinical animal and human studies. There is no proof to date of a cause-effect relationship between GBCA administration at clinical doses and cutaneous consequences in patients with normal renal function. Multiple factors, yet to be determined, should be considered for sporadic patients with normal renal function who develop clinical skin manifestations temporally related to GBCA administration.

[1]  G. Marfia,et al.  Skin Thickening of the Scalp and High Signal Intensity of Dentate Nucleus in Multiple Sclerosis , 2022, Investigative radiology.

[2]  R. Semelka,et al.  Commentary on the Association of Symptoms Associated With Gadolinium Exposure/Gadolinium Deposition Disease and Gadolinium-Based Contrast Agents. , 2022, Investigative radiology.

[3]  D. B. Jackson,et al.  Gadolinium Deposition Disease: A Case Report and the Prevalence of Enhanced MRI Procedures Within the Veterans Health Administration. , 2022, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.

[4]  E. Lancelot,et al.  Use of Real-Life Safety Data From International Pharmacovigilance Databases to Assess the Importance of Symptoms Associated With Gadolinium Exposure , 2022, Investigative radiology.

[5]  A. Al-Muhanna Gadolinium Retention after Contrast-Enhanced Magnetic Resonance Imaging: A Narratative Review , 2022, Saudi journal of medicine & medical sciences.

[6]  J. Weinreb,et al.  Symptoms Associated with Gadolinium Exposure (SAGE): A Suggested Term. , 2021, Radiology.

[7]  A. Radbruch,et al.  Gadolinium Tissue Distribution in a Large-Animal Model after a Single Dose of Gadolinium-based Contrast Agents. , 2021, Radiology.

[8]  Swati Rane Levendovszky,et al.  Comparison of Human Tissue Gadolinium Retention and Elimination between Gadoteridol and Gadobenate. , 2021, Radiology.

[9]  M. Kirchin,et al.  Gadolinium Clearance in the First 5 Weeks After Repeated Intravenous Administration of Gadoteridol, Gadoterate Meglumine, and Gadobutrol to rats , 2021, Journal of magnetic resonance imaging : JMRI.

[10]  D. Fine,et al.  Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. , 2020, Radiology.

[11]  M. Fakhoury,et al.  Gadolinium Retention in the Central and Peripheral Nervous System: Implications for Pain, Cognition, and Neurogenesis. , 2020, Radiology.

[12]  H. Schlemmer,et al.  Is Small Fiber Neuropathy Induced by Gadolinium-Based Contrast Agents? , 2020, Investigative radiology.

[13]  C. Simpson,et al.  Human Hair as a Possible Surrogate Marker of Retained Tissue Gadolinium , 2020, Investigative radiology.

[14]  P. Parizel,et al.  Gadolinium Deposition Safety: Seeking the Patient’s Perspective , 2020, American Journal of Neuroradiology.

[15]  P. Parizel,et al.  Exposure to gadolinium and neurotoxicity: current status of preclinical and clinical studies , 2020, Neuroradiology.

[16]  P. Parizel,et al.  Within-network brain connectivity in Crohn’s disease patients with gadolinium deposition in the cerebellum , 2020, Neuroradiology.

[17]  M. Kirchin,et al.  Macrocyclic MR contrast agents: evaluation of multiple-organ gadolinium retention in healthy rats , 2020, Insights into Imaging.

[18]  J. Weinreb,et al.  Gadolinium Deposition and Nephrogenic Systemic Fibrosis: A Radiologist's Primer. , 2019, Radiographics : a review publication of the Radiological Society of North America, Inc.

[19]  M. Sapienza,et al.  A Structured Survey on Adverse Events Occurring Within 24 Hours After Intravenous Exposure to Gadodiamide or Gadoterate Meglumine: A Controlled Prospective Comparison Study , 2019, Investigative radiology.

[20]  D. Miller,et al.  Image Gallery: A case of gadolinium‐associated plaques requiring confirmation with mass spectrometry , 2019, The British journal of dermatology.

[21]  R. Atit,et al.  Dermal fibroblast in cutaneous development and healing , 2018, Wiley interdisciplinary reviews. Developmental biology.

[22]  M. Kirchin,et al.  Non‐clinical assessment of safety and gadolinium deposition after cumulative administration of gadobenate dimeglumine (MultiHance®) to neonatal and juvenile rats , 2018, Regulatory toxicology and pharmacology : RTP.

[23]  E. Gianolio,et al.  The Issue of Gadolinium Retained in Tissues: Insights on the Role of Metal Complex Stability by Comparing Metal Uptake in Murine Tissues Upon the Concomitant Administration of Lanthanum- and Gadolinium-Diethylentriamminopentaacetate , 2017, Investigative radiology.

[24]  Tyler J. Fraum,et al.  Gadolinium‐based contrast agents: A comprehensive risk assessment , 2017, Journal of magnetic resonance imaging : JMRI.

[25]  M. Kirchin,et al.  Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats , 2017, Journal of magnetic resonance imaging : JMRI.

[26]  R. Semelka,et al.  Gadolinium deposition disease: Initial description of a disease that has been around for a while. , 2016, Magnetic resonance imaging.

[27]  R. Semelka,et al.  Presumed Gadolinium Toxicity in Subjects With Normal Renal Function: A Report of 4 Cases , 2016, Investigative radiology.

[28]  R. Semelka,et al.  Self-reported gadolinium toxicity: A survey of patients with chronic symptoms. , 2016, Magnetic resonance imaging.

[29]  A. Hatamochi,et al.  Effects of Gadodiamide on cell proliferation and collagen production in cultured human dermal fibroblasts , 2016, Archives of Dermatological Research.

[30]  D. Hippe,et al.  Macrocyclic and Other Non–Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function , 2016, Investigative radiology.

[31]  K. Maravilla,et al.  High Levels of Gadolinium Deposition in the Skin of a Patient With Normal Renal Function , 2016, Investigative radiology.

[32]  R. Brodell,et al.  Gadolinium-associated plaques: a new, distinctive clinical entity. , 2015, JAMA dermatology.

[33]  J. Barnes,et al.  Type of MRI contrast, tissue gadolinium, and fibrosis. , 2014, American journal of physiology. Renal physiology.

[34]  S. Jimenez,et al.  Induction of a type I interferon signature in normal human monocytes by gadolinium‐based contrast agents: comparison of linear and macrocyclic agents , 2014, Clinical and experimental immunology.

[35]  M. Rehman,et al.  Stimulation of Fibroblast Proliferation by Insoluble Gadolinium Salts , 2012, Biological Trace Element Research.

[36]  S. MacNeil,et al.  Gadolinium Contrast Agent Associated Stimulation of Human Fibroblast Collagen Production , 2011, Investigative radiology.

[37]  J. Varani,et al.  Fibroblast Response to Lanthanoid Metal Ion Stimulation: Potential Contribution to Fibrotic Tissue Injury , 2011, Biological Trace Element Research.

[38]  J. Varani,et al.  Fibroblast Response to Gadolinium: Role for Platelet-Derived Growth Factor Receptor , 2010, Investigative radiology.

[39]  R. Swartz,et al.  Responses of Human Skin in Organ Culture and Human Skin Fibroblasts to a Gadolinium-Based MRI Contrast Agent: Comparison of Skin From Patients With End-Stage Renal Disease and Skin From Healthy Subjects , 2010, Investigative radiology.

[40]  J. Quinn,et al.  Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. , 2010, Radiology.

[41]  T. Steger-Hartmann,et al.  A Review of Preclinical Safety Data for Magnevist (Gadopentetate Dimeglumine) in the Context of Nephrogenic Systemic Fibrosis , 2010, Investigative radiology.

[42]  Rakesh Sharma Gadolinium toxicity: epidermis thickness measurement by magnetic resonance imaging at 500 MHz , 2010, Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging.

[43]  S. Jimenez,et al.  Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis , 2010, Annals of the rheumatic diseases.

[44]  R. Swartz,et al.  Collagenolytic Activity Is Suppressed in Organ-Cultured Human Skin Exposed to a Gadolinium-Based MRI Contrast Agent , 2010, Investigative radiology.

[45]  R. Swartz,et al.  Regulation of Collagen Turnover in Human Skin Fibroblasts Exposed to a Gadolinium-Based Contrast Agent , 2009, Investigative radiology.

[46]  R. Swartz,et al.  Effects of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents on Human Skin in Organ Culture and Human Skin Fibroblasts , 2009, Investigative radiology.

[47]  W. High,et al.  Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. , 2008, Journal of the American Academy of Dermatology.

[48]  J. L. Abraham,et al.  Gadolinium is not deposited in the skin of patients with normal renal function after exposure to gadolinium-based contrast agents. , 2008, Journal of the American Academy of Dermatology.

[49]  T. Frenzel,et al.  Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions , 2008, European Radiology.

[50]  M. Edward,et al.  Gadodiamide contrast agent ‘activates’ fibroblasts: a possible cause of nephrogenic systemic fibrosis , 2008, The Journal of pathology.

[51]  C. Robic,et al.  Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review , 2008, BioMetals.

[52]  R. Semelka,et al.  Physicians with self-diagnosed gadolinium deposition disease: a case series , 2021, Radiologia brasileira.

[53]  C. Mallio,et al.  Impact of Brain Irradiation, Chemotherapy, and Presence of Primary Brain Tumors on Changes in Signal Intensity after Exposure to Gadolinium-based Contrast Agents. , 2019, Radiology.

[54]  T. Moyer,et al.  Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. , 2011, Journal of the American Academy of Dermatology.

[55]  B. Thiers Quantification of gadolinium in nephrogenic systemic fibrosis: Re-examination of a reported cohort with analysis of clinical factors , 2009 .

[56]  S. Cowper,et al.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.

[57]  S. Cowper,et al.  Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.